Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HD204 vs Avastin in Healthy Male Subjects
NCT03390673Phase 1Completed
- Sponsor
- Prestige Biopharma Limited
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HLX04 in cancer (3 arms), sponsored by Prestige Biopharma Limited. Primary endpoints: Area Under the Curve from Time Zero to Infinity at 71 days, Area Under the Curve from Time Zero to Last Quantifiable Concentration at 71 days and 1 more. Started Sep 2018; status: completed.
02
Drugs
HLX04
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03390673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390673.